Apolipoprotein e polymorphism in hemodialyzed patients and healthy controls

14Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.
Get full text

Abstract

A possible association between end-stage renal disease (ESRD) and apolipoprotein E (APOE) polymorphism was found in some but not all studies. We have analyzed the APOE genotypes in 995 hemodialyzed patients (cases) and a sample of 6242 healthy individuals (controls) in the Czech Republic. There was a statistically significant difference in the frequency of APOE alleles between cases and controls, with more carriers of the APOE2 allele in ESRD patients (15.9%) than in controls (12.2%) (P = 0.005). The odds ratio of ESRD for the APOE2 allele, compared with APOE3E3 homozygotes, was 1.37 (95% confidence interval 1.13-1.67). The strength of the association increased with the time spent on hemodialysis: the odds ratio of all-cause ESRD in patients dialyzed for eight or more years was 1.27 (0.94-1.71), for 1-8 years 1.41 (1.09-1.81), and less than 1 year (nonsurvivors) 1.94 (0.88-4.18). This study suggests that the APOE2 allele is a possible genetic risk factor for all-cause ESRD in Caucasians. © 2009 Springer Science+Business Media, LLC.

Cite

CITATION STYLE

APA

Hubacek, J. A., Bloudickova, S., Kubinova, R., Pikhart, H., Viklicky, O., & Bobak, M. (2009). Apolipoprotein e polymorphism in hemodialyzed patients and healthy controls. Biochemical Genetics, 47(9–10), 688–693. https://doi.org/10.1007/s10528-009-9266-y

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free